Company intelligence / Profile preview

Delorbis Pharmaceuticals Ltd

Lefkosia(Nicosia), Nicosia District(Lefkosia), Cyrpusdelorbispharma.eu ↗

Ownership: Private
Development stage: Commercial

Overview

Delorbis has a large commercial portfolio of over 100 branded generic medicines and biosimilars available in more than 35 markets globally. The company focuses on high-quality EU-approved products with an emphasis on affordability and accessibility. Clinical results are not directly reported as the focus is on generics/biosimilars rather than novel therapeutics

Therapeutic areas: OncologyOtherPsychiatryCardiovascularInfectious Diseases
Modalities: Small molecules (branded generics)biosimilars
Industry: Contract Manufacturing Organization

Partnerships

Tiefenbacher Groupvarious global strategic partnerships to expand market reach and product pipeline

Beyond the preview

Go deeper on Delorbis Pharmaceuticals Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Delorbis Pharmaceuticals Ltd.

Explore the full profile